Last reviewed 2026-04-23 · How we verify

Efavirenz + Zidovudine/Lamivudine

Efavirenz + Zidovudine/Lamivudine is a Antiretroviral combination therapy (NNRTI + 2 NRTIs) Small molecule drug developed by ViiV Healthcare. It is currently in Phase 3 development for HIV-1 infection in treatment-naïve patients, HIV-1 infection in treatment-experienced patients.

This combination uses a non-nucleoside reverse transcriptase inhibitor (efavirenz) plus two nucleoside reverse transcriptase inhibitors (zidovudine and lamivudine) to block HIV replication at multiple steps.

This combination uses a non-nucleoside reverse transcriptase inhibitor (efavirenz) plus two nucleoside reverse transcriptase inhibitors (zidovudine and lamivudine) to block HIV replication at multiple steps. Used for HIV-1 infection in treatment-naïve patients, HIV-1 infection in treatment-experienced patients.

At a glance

Mechanism of action

Efavirenz binds directly to HIV reverse transcriptase and inhibits its activity, while zidovudine and lamivudine are nucleoside analogs that are incorporated into the growing DNA chain during reverse transcription, causing chain termination. Together, these three agents provide complementary inhibition of reverse transcriptase to suppress viral replication and reduce HIV RNA levels.

Approved indications

• HIV-1 infection in treatment-naïve patients
• HIV-1 infection in treatment-experienced patients

Common side effects

• Dizziness and CNS effects
• Rash
• Nausea
• Headache
• Anemia
• Neutropenia
• Lipodystrophy
• Hepatotoxicity

Key clinical trials

• Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
• A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
• Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
• Research on the Psychological Status of Patients With HIV-1 Infection
• A Prospective Cohort of Children With HIV Infection
• Effects of Maraviroc vs. Efavirenz on CD4/CD8 Ratio (PHASE3)
• The Effect of Aspirin on HIV Disease Progression Among HIV- Infected Individuals Initiating Anti- Retroviral Therapy (PHASE2)
• Preventing Sexual Transmission of HIV With Anti-HIV Drugs (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Efavirenz + Zidovudine/Lamivudine CI brief — competitive landscape report
• Efavirenz + Zidovudine/Lamivudine updates RSS · CI watch RSS
• ViiV Healthcare portfolio CI

Frequently asked questions about Efavirenz + Zidovudine/Lamivudine

Related

• Drug class: All Antiretroviral combination therapy (NNRTI + 2 NRTIs) drugs
• Target: All drugs targeting HIV reverse transcriptase
• Manufacturer: ViiV Healthcare — full pipeline
• Therapeutic area: All drugs in Infectious Disease / Virology
• Indication: Drugs for HIV-1 infection in treatment-naïve patients
• Indication: Drugs for HIV-1 infection in treatment-experienced patients
• Compare: Efavirenz + Zidovudine/Lamivudine vs similar drugs
• Pricing: Efavirenz + Zidovudine/Lamivudine cost, discount & access